The History of Gastric Surgery James 0
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Association Between Gastric Myoelectric Activity Disturbances and Dyspeptic T Symptoms in Gastrointestinal Cancer Patients ⁎ Aneta L
Advances in Medical Sciences 64 (2019) 44–53 Contents lists available at ScienceDirect Advances in Medical Sciences journal homepage: www.elsevier.com/locate/advms Original research article Association between gastric myoelectric activity disturbances and dyspeptic T symptoms in gastrointestinal cancer patients ⁎ Aneta L. Zygulskaa, , Agata Furgalab, Krzysztof Krzemienieckia,c,1, Beata Wlodarczykb, Piotr Thorb a Department of Oncology, University Hospital in Cracow, Cracow, Poland b Department of Pathophysiology, Jagiellonian University Medical College, Cracow, Poland c Department of Oncology, Jagiellonian University Medical College, Cracow, Poland ARTICLE INFO ABSTRACT Keywords: Purpose: Dyspeptic symptoms present a severe problem in gastrointestinal (GI) cancer patients. The aim of the Gastrointestinal carcinoma study was to analyze an association between gastric myoelectric activity changes and dyspeptic symptoms in Gastric motility gastrointestinal cancer patients. Gastric myoelectric activity Material and Methods: The study included 80 patients (37 men and 43 women, mean age 61.2 ± 7.8 years) Electrogastrography diagnosed with GI tract malignancies: colon (group A), rectal (group B) and gastric cancers (group C). Gastric Dyspeptic symptoms myoelectric activity in a preprandial and postprandial state was determined by means of a 4-channel electro- gastrography. Autonomic nervous system was studied based on heart rate variability analysis. The results were compared with the data from healthy asymptomatic controls. Results: In a fasted state, GI cancer patients presented with lesser percentages of normogastria time (A:44.23 vs. B:46.5 vs. C:47.10 vs. Control:78.2%) and average percentage slow wave coupling (ACSWC) (A:47.1 vs. B:50.8 vs. C:47.2 vs. Control:74.9%), and with higher values of dominant power (A:12.8 vs. -
About Your Gastrectomy Surgery
Patient & Caregiver Education About Your Gastrectomy Surgery About Your Surgery .................................................................................................................3 Before Your Surgery .................................................................................................................5 Preparing for Your Surgery ............................................................................................................6 Common Medications Containing Aspirin and Other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) ............................................................... 14 Herbal Remedies and Cancer Treatment ................................................................................ 19 Information for Family and Friends for the Day of Surgery ............................................22 After Your Surgery .................................................................................................................27 What to Expect ............................................................................................................................... 28 How to Use Your Incentive Spirometer .................................................................................. 32 Patient-Controlled Analgesia (PCA) ....................................................................................... 35 Eating After Your Gastrectomy ..................................................................................................37 Resources ................................................................................................................................53 -
Management of Afferent Loop Obstruction: Reoperation Or Endoscopic and Percutaneous Interventions
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/282163026 Management of afferent loop obstruction: Reoperation or endoscopic and percutaneous interventions Article in World Journal of Gastrointestinal Surgery · September 2015 DOI: 10.4240/wjgs.v7.i9.190 CITATIONS READS 32 427 2 authors, including: Konstantinos Tsalis Aristotle University of Thessaloniki 115 PUBLICATIONS 976 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: Laparoscopic liver resection using ICG green visualization of hepatic structures View project Laparoscopic liver resection using ICG green visualization of hepatic structures View project All content following this page was uploaded by Konstantinos Tsalis on 26 May 2017. The user has requested enhancement of the downloaded file. Submit a Manuscript: http://www.wjgnet.com/esps/ World J Gastrointest Surg 2015 September 27; 7(9): 190-195 Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx ISSN 1948-9366 (online) DOI: 10.4240/wjgs.v7.i9.190 © 2015 Baishideng Publishing Group Inc. All rights reserved. MINIREVIEWS Management of afferent loop obstruction: Reoperation or endoscopic and percutaneous interventions? Konstantinos Blouhos, Konstantinos Andreas Boulas, Konstantinos Tsalis, Anestis Hatzigeorgiadis Konstantinos Blouhos, Konstantinos Andreas Boulas, Anestis Abstract Hatzigeorgiadis, Department of General Surgery, General Hospital of Drama, 66100 Drama, Greece Afferent loop obstruction is a purely mechanical comp- lication that infrequently occurs following construction Konstantinos Tsalis, D’ Surgical Department, “G. Papanikolaou” of a gastrojejunostomy. The operations most commonly Hospital, Medical School, Aristotle University of Thessaloniki, associated with this complication are gastrectomy 54645 Thessaloniki, Greece with Billroth Ⅱ or Roux-en-Y reconstruction, and pancreaticoduodenectomy with conventional loop or Author contributions: Blouhos K designed the research; Boulas Roux-en-Y reconstruction. -
Gastroenterostomy and Vagotomy for Chronic Duodenal Ulcer
Gut, 1969, 10, 366-374 Gut: first published as 10.1136/gut.10.5.366 on 1 May 1969. Downloaded from Gastroenterostomy and vagotomy for chronic duodenal ulcer A. W. DELLIPIANI, I. B. MACLEOD1, J. W. W. THOMSON, AND A. A. SHIVAS From the Departments of Therapeutics, Clinical Surgery, and Pathology, The University ofEdinburgh The number of operative procedures currently in Kingdom answered a postal questionnaire. Eight had vogue in the management of chronic duodenal ulcer died since operation, and three could not be traced. The indicates that none has yet achieved definitive status. patients were questioned particularly with regard to Until recent years, partial gastrectomy was the eating capacity, dumping symptoms, vomiting, ulcer-type dyspepsia, diarrhoea or other change in bowel habit, and favoured operation, but an increasing awareness of a clinical assessment was made based on a modified its significant operative mortality and its metabolic Visick scale. The mean time since operation was 6-9 consequences, along with Dragstedt and Owen's years. demonstration of the effectiveness of vagotomy in Thirty-five patients from this group were admitted to reducing acid secretion (1943), has resulted in the hospital for a full investigation of gastrointestinal and widespread use of vagotomy and gastric drainage. related function two to seven years following their The success of duodenal ulcer surgery cannot be operation. Most were volunteers, but some were selected judged only on low stomal (or recurrent) ulceration because of definite complaints. There were more females rates; the other sequelae of gastric operations must than males (21 females and 14 males). The following be considered. -
Technic VERTICAL GASTROPLASTY WITH
ABCDDV/802 ABCD Arq Bras Cir Dig Technic 2011;24(3): 242-245 VERTICAL GASTROPLASTY WITH JEJUNOILEAL BYPASS - NEW TECHNICAL PROCEDURE Gastroplastia vertical com desvio jejunoileal - novo procedimento técnico Bruno ZILBERSTEIN, Arthur Sergio da SILVEIRA-FILHO, Juliana Abbud FERREIRA, Marnay Helbo de CARVALHO, Cely BUSSONS, Henrique JOAQUIM, Fernando RAMOS From Gastromed-Instituto Zilberstein, São ABSTRACT - Introduction - Vertical gastroplasty is increasingly used in the surgical Paulo, SP, Brasil. treatment of morbid obesity, being used alone or as part of the duodenal switch surgery or even in intestinal bipartition (Santoro technique). When used alone has only a restrictive character. Method - Is proposed association of jejunoileal bypass to vertical gastroplasty, in order to give a metabolic component to the procedure and eventually empower it to medium and long term. Eight morbidly obese patients were operated after removal of adjustable gastric band or as a primary procedure associated to vertical banded gastroplasty with jejunoileal bypass laterolateral and anastomosis between the jejunum 80 cm from duodenojejunal angle and the ileum at 120 cm from ileocecal valve, by laparoscopy. Results - The patients presented themselves without complications both in trans or in the immediate postoperative period, and also in the months that followed. The evolution BMI showed a significant reduction ranging from 39.57 kg/m2 to 28 kg/m2. No patient reported diarrhea or malabsorptive disorder in HEADINGS - Sleeve gastrectomy. Jejunoileal the period. Conclusion - It can be offered a new therapeutic option, with restraining diversion. Obesity. Surgery. and metabolic aspects, in which there are no consequences as the ones founded in procedures with duodenal diversion or intestinal transit alterations. -
Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy with Hospitalization for Upper Gastrointestinal Tract Bleeding
Supplementary Online Content Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. doi:10.1001/jama.2018.17242 eAppendix. PPI Co-therapy and Anticoagulant-Related UGI Bleeds This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Appendix: PPI Co-therapy and Anticoagulant-Related UGI Bleeds Table 1A Exclusions: end-stage renal disease Diagnosis or procedure code for dialysis or end-stage renal disease outside of the hospital 28521 – anemia in ckd 5855 – Stage V , ckd 5856 – end stage renal disease V451 – Renal dialysis status V560 – Extracorporeal dialysis V561 – fitting & adjustment of extracorporeal dialysis catheter 99673 – complications due to renal dialysis CPT-4 Procedure Codes 36825 arteriovenous fistula autogenous gr 36830 creation of arteriovenous fistula; 36831 thrombectomy, arteriovenous fistula without revision, autogenous or 36832 revision of an arteriovenous fistula, with or without thrombectomy, 36833 revision, arteriovenous fistula; with thrombectomy, autogenous or nonaut 36834 plastic repair of arteriovenous aneurysm (separate procedure) 36835 insertion of thomas shunt 36838 distal revascularization & interval ligation, upper extremity 36840 insertion mandril 36845 anastomosis mandril 36860 cannula declotting; 36861 cannula declotting; 36870 thrombectomy, percutaneous, arteriovenous -
Seer Program Code Manual
THE SEER PROGRAM CODE MANUAL Revised Edition June 1992 CANCER STATISTICS BRANCH SURVEILLANCE PROGRAM DIVISION OF CANCER PREVENTION AND CONTROL NATIONAL CANCER INSTITUTE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE NATIONAL INSTITUTES OF HEALTH Effective Date: Cases Diagnosed January 1, 1992 The SEER Program Code Manual Revised Edition June 1992 Editors Jack Cunningham Lynn Ries Benjamin Hankey Jennifer Seiffert Barbara Lyles Evelyn Shambaugh Constance Percy Valerie Van Holten Acknowledgements The editors wish to acknowledge the assistance of Terry Swenson, Maureen Troublefield, Diane Licitra, and Jerome Felix of Information Management Services, Inc., in the preparation of the SEER Program Code Manual. The editors also wish to acknowledge the assistance of Dr. John Berg in preparation of the section on multiple primary determination for lymphatic and hematopoietic diseases. TABLE OF CONTENTS PREFACE TO THE REVISED EDITION ....................................... vii COMPUTER RECORD FORMAT ............................................ 1 INTRODUCTION AND GENERAL INSTRUCTIONS .............................. 5 REFERENCES .......................................................... 37 SEER CODE SUMMARY .................................................. 39 I BASIC RECORD IDENTIFICATION ...................................... 57 1.01 SEER Participant ........................................... 58 1.02 Case Number .............................................. 59 1.03 Record Number ............................................ 60 -
374 Part 876—Gastroenterology
§ 874.5550 21 CFR Ch. I (4–1–08 Edition) Drug Administration on or before July subpart E of part 807 of this chapter 13, 1999 for any tongs antichoke device subject to § 874.9. that was in commercial distribution [51 FR 40389, Nov. 6, 1986, as amended at 65 before May 28, 1976, or that has, on or FR 2316, Jan. 14, 2000] before July 13, 1999, been found to be substantially equivalent to a tongs antichoke device that was in commer- PART 876—GASTROENTEROLOGY- cial distribution before May 28, 1976. UROLOGY DEVICES Any other tongs antichoke device shall have an approved PMA or declared Subpart A—General Provisions completed PDP in effect before being Sec. placed in commercial distribution. 876.1 Scope. 876.3 Effective dates of requirement for pre- [51 FR 40389, Nov. 6, 1986, as amended at 64 market approval. FR 18329, Apr. 14, 1999] 876.9 Limitations of exemptions from sec- tion 510(k) of the Federal Food, Drug, § 874.5550 Powered nasal irrigator. and Cosmetic Act (the act). (a) Identification. A powered nasal irrigator is an AC-powered device in- Subpart B—Diagnostic Devices tended to wash the nasal cavity by 876.1075 Gastroenterology-urology biopsy means of a pressure-controlled pul- instrument. sating stream of water. The device con- 876.1300 Ingestible telemetric gastro- sists of a control unit and pump con- intestinal capsule imaging system. nected to a spray tube and nozzle. 876.1400 Stomach pH electrode. (b) Classification. Class I (general con- 876.1500 Endoscope and accessories. trols). The device is exempt from the 876.1620 Urodynamics measurement system. -
Safe, Simple & Efficient Totally Laparoscopic Billroth II Gastrectomy
China Gastric Cancer Research Highlight Safe, simple & efficient totally laparoscopic Billroth II gastrectomy by only stapling devices Kirubakaran Malapan1, Chih-Kun Huang1,2 1Department of Bariatric and Metabolic International Surgery Centre, E-Da Hospital, Kaohsiung City, 82445, Taiwan; 2The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China Corresponding to: Chih-Kun Huang, M.D., Director. Department of Bariatric and Metabolic International Surgery Centre, E-da Hospital, No 1, E-Da Rd., Yan-chau District, Kaohsiung City, Taiwan, 82445. Email: [email protected]. Submitted May 08, 2013. Accepted for publication May 28, 2013. doi: 10.3978/j.issn.2224-4778.2013.05.28 Scan to your mobile device or view this article at: http://www.amepc.org/tgc/article/view/2081/2870 Gastric cancer is the fourth most common cancer diagnosis combination of both. Du J et al. reported their experience worldwide in men with an expected incidence of 640,000 of intracorporeal gastrojejunal anastomosis using a two cases and the fifth most common in women with an expected layer hand-sewn technique (9), whereas Ruiz et al. described incidence of 350,000 cases in 2011 (1). Approximately, 8% a 4-layer closure using continuous absorbable sutures (10). of total cases and 10% of annual cancer deaths worldwide Hand-sewn anastomosis requires advanced laparoscopic are attributed to this dreaded disease. Surgical resection skills and is considered to be time-consuming, but has offers the only durable cure from gastric cancer (2). Since the advantage of avoiding the risk of wound infection and the introduction of Billroth’s procedure of gastrectomy and hernias, which occur as a result of manipulation by a circular reconstruction in 1881, surgical techniques in gastric surgery stapler. -
Electrohydraulic Lithotripsy of an Impacted Enterolith Causing Acute Afferent Loop Syndrome
CASE REPORT Print ISSN 2234-2400 / On-line ISSN 2234-2443 Clin Endosc 2014;47:367-370 http://dx.doi.org/10.5946/ce.2014.47.4.367 Open Access Electrohydraulic Lithotripsy of an Impacted Enterolith Causing Acute Afferent Loop Syndrome Young Sin Cho, Tae Hoon Lee, Soon Oh Hwang, Sunhyo Lee, Yunho Jung, Il-Kwun Chung, Sang-Heum Park and Sun-Joo Kim Division of Gastroenterology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea Afferent loop syndrome caused by an impacted enterolith is very rare, and endoscopic removal of the enterolith may be difficult if a stricture is present or the normal anatomy has been altered. Electrohydraulic lithotripsy is commonly used for endoscopic fragmenta- tion of biliary and pancreatic duct stones. A 64-year-old man who had undergone subtotal gastrectomy and gastrojejunostomy presented with acute, severe abdominal pain for a duration of 2 hours. Initially, he was diagnosed with acute pancreatitis because of an elevated amy- lase level and pain, but was finally diagnosed with acute afferent loop syndrome when an impacted enterolith was identified by comput- ed tomography. We successfully removed the enterolith using direct electrohydraulic lithotripsy conducted using a transparent cap-fitted endoscope without complications. We found that this procedure was therapeutically beneficial. Key Words: Afferent loop syndrome; Enterolith; Electrohydraulic lithotripsy INTRODUCTION cutaneous enterostomy has been considered as a palliative method. However, maturation of the percutaneous tract can Afferent loop syndrome (ALS) is characterized by the ac- occur very slowly prior to the procedure, and may cause dis- cumulation of bile acid and pancreatic juice, and distention comfort and pain. -
Laparoscopic Gastrectomy with D2 Lymphadenectomy for Gastric Cancer
Abdelhamed et al. Journal of the Egyptian National Cancer Institute (2020) 32:10 Journal of the Egyptian https://doi.org/10.1186/s43046-020-00023-7 National Cancer Institute RESEARCH Open Access Laparoscopic gastrectomy with D2 lymphadenectomy for gastric cancer: initial Egyptian experience at the National Cancer Institute Mohamed Aly Abdelhamed* , Ahmed Abdellatif, Ahmed Touny, Ahmed Mostafa Mahmoud, Ihab Saad Ahmed, Sherif Maamoun and Mohamed Shalaby Abstract Background: Laparoscopic gastrectomy has been used as a superior alternative to open gastrectomy for the treatment of early gastric cancer. However, the application of laparoscopic D2 lymphadenectomy remains controversial. This study aimed to evaluate the feasibility and outcomes of laparoscopic gastrectomy with D2 lymphadenectomy for gastric cancer. Results: Between May 2016 and May 2018, twenty-five consecutive patients with gastric cancer underwent laparoscopic D2 gastrectomy: eighteen patients (72%) underwent distal gastrectomy, four patients (16%) underwent total gastrectomy, and three patients (12%) underwent proximal gastrectomy. The median number of lymph nodes retrieved was 18 (5–35). A positive proximal margin was detected in 2 patients (8%). The median operative time and amount of blood loss were 240 min (200–330) and 250 ml (200–450), respectively. Conversion to an open procedure was performed in seven patients (28%). The median hospital stay period was 8 days (6–30), and the median time to start oral fluids was 4 days (3–30). Postoperative complications were detected in 4 patients (16%). There were two cases of mortality (8%) in the postoperative period, and two patients required reoperation (8%). Conclusions: Laparoscopic gastrectomy with D2 lymphadenectomy can be carried out safely and in accordance with oncologic principles. -
Gastric Carcinoma: an Unexpected Diagnosis
20 Brief Case Volume 2 No. 1, 2004 BRIEF CASE Gastric Carcinoma: An Unexpected Diagnosis Dr. Catherine Hanley, BSc(OT), MD THE CASE often have episodes of postprandial pain (especially following Mr. S is a 66-year-old man who recently presented to his fatty meals), and their pain usually begins abruptly and subsides family doctor with a one month history of epigastric pain and gradually after a few minutes to several hours.1 Nausea and nausea. His pain was persistent, dull and increased with eating. vomiting can occur during attacks of biliary colic, but not usu- He had never experienced this pain before. He had also had a ally between attacks. Weight loss and anorexia are not common few months’ history of weight loss and noticed a decreased symptoms. Pain is episodic and usually localized to the right abdominal girth, with his clothes fitting more loosely. He upper quadrant, but can be felt across the epigastrium and denied any dysphagia, changes in bowel movements, melena or through to the back, or referred to the area overlying the scapu- hematochezia. He did not have a history of peptic ulcer disease lae. Liver enzymes, as well as leukocyte counts, are usually or gastroesophageal reflux disease (GERD). His past medical normal in patients with biliary colic. An ultrasound is the gold history included coronary artery disease with a myocardial standard diagnostic test for cholelithiasis, with both a specifici- infarction in 1993, and a coronary artery bypass graft (CABG) ty and sensitivity of 95%.1 six years prior. He had a 30-pack-year history of smoking, but Pancreatitis is also on the differential diagnosis for Mr.